By Will Feuer
Shares of arrhythmia management company Acutus Medical Inc. jumped some 20% in premarket trading Monday after the company said the Food and Drug Administration has cleared the commercial launch of an expanded suite of left-heart access products.
The company's suite of products will now include its AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device.
Acutus Medical said gaining access to the left atrium of the heart typically requires physicians to cross the septum, a complicated process that often involves the exchange of wires and needles while trying to achieve the proper angle and location on the septum.
The launch of AcQCross and its compatibility with the Watchman device will help doctors reposition during left-heart access procedures without withdrawing or exchanging needles or wires, the company said. It said left-atrial appendage closure procedures are expected to total more than 50,000 in 2022.
"The expanded AcQCross product line allows us to bring this innovative technology to a wider range of procedure categories that should drive sustained growth in this portfolio," interim Chief Executive David Roman said.
Shares rose 30% to 70 cents a share in premarket trading. The stock closed on Friday about 84% lower this year.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires